Oberholtzer E - Search Results

1

Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors.

Cesano A, Oberholtzer E, Contarini M, Geuna M, Bellone G, Matera L. Cesano A, et al. Among authors: oberholtzer e. Immunopharmacology. 1994 Jul-Aug;28(1):67-75. doi: 10.1016/0162-3109(94)90040-x. Immunopharmacology. 1994. PMID: 7928303

2

Normal development of lymphokine activated killing (LAK) in peripheral blood lymphocytes from hyperprolactinemic patients.

Matera L, Ciccarelli E, Muccioli G, Cesano A, Grottoli S, Oberholtzer E, Camanni F. Matera L, et al. Among authors: oberholtzer e. Int J Immunopharmacol. 1992 Oct;14(7):1235-40. doi: 10.1016/0192-0561(92)90059-t. Int J Immunopharmacol. 1992. PMID: 1452408

3

Modulatory effect of prolactin on the resting and mitogen-induced activity of T, B, and NK lymphocytes.

Matera L, Cesano A, Bellone G, Oberholtzer E. Matera L, et al. Among authors: oberholtzer e. Brain Behav Immun. 1992 Dec;6(4):409-17. doi: 10.1016/0889-1591(92)90039-q. Brain Behav Immun. 1992. PMID: 1490033

4

Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors.

Oberholtzer E, Contarini M, Veglia F, Cossarizza A, Franceschi C, Geuna M, Provinciali M, Di Stefano G, Sissom J, Brizzi MF, Pegoraro L, Matera L. Oberholtzer E, et al. Adv Neuroimmunol. 1996;6(3):233-47. doi: 10.1016/s0960-5428(96)00019-8. Adv Neuroimmunol. 1996. PMID: 8968423

5

Effect of human interleukin 3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity.

Cesano A, Lista P, Bellone G, Geuna M, Brizzi MF, Rossi PR, Pegoraro L, Oberholtzer E, Matera L. Cesano A, et al. Among authors: oberholtzer e. Leukemia. 1992 Jun;6(6):567-73. Leukemia. 1992. PMID: 1376379

6

Developing a self-service query interface for re-using de-identified electronic health record data.

Cimino JJ, Ayres EJ, Beri A, Freedman R, Oberholtzer E, Rath S. Cimino JJ, et al. Among authors: oberholtzer e. Stud Health Technol Inform. 2013;192:632-6. Stud Health Technol Inform. 2013. PMID: 23920633 Free PMC article.

7

Pharmaceutical design and development of a Sinemet controlled-release formulation.

Dempski RE, Scholtz EC, Oberholtzer ER, Yeh KC. Dempski RE, et al. Among authors: oberholtzer er. Neurology. 1989 Nov;39(11 Suppl 2):20-4. Neurology. 1989. PMID: 2685648 Review.

8

Cefoxitin sodium: solution and solid-state chemical stability studies.

Oberholtzer ER, Brenner GS. Oberholtzer ER, et al. J Pharm Sci. 1979 Jul;68(7):863-6. doi: 10.1002/jps.2600680720. J Pharm Sci. 1979. PMID: 458604

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters